Fulcrum Therapeutics (FULC)

• Market cap: $425M
• 1 day: -0.13%
• 5 days: -8.5%
• 1 month: -17.26%
• 3 months: 13.26%
• 6 months: 46.92%
• Year to date: 62.4%
• 1 year: 129.15%
• 5 years: -33.39%
• 10 years: -41.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45